USPTO serial 99302295
CELLCURA
Reviewed by CopyMark Law Group
Status 748
- Filing date
- Status date
- Registration date
- —
- Examiner
- LEE, SANG MIN
- Law office
- TMO LAW OFFICE 111
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CELLCURA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cy Bates
Cy Bates CP LAW GROUP PCP.O. Box 5195Oceanside, CA 92052United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical cleansers for skin and wounds; Liquid bandages for skin wounds; Pharmaceutical preparations for skin wounds; Bandages for skin wounds; Pharmaceutical preparations for wounds; Biological preparations for the treatment of musculoskeletal and orthopedic conditions including osteoarthritis, tendon and ligament injuries, fractures and non-unions, bulging or herniated discs, degenerative disc disease, carpal tunnel syndrome, cartilage injuries, muscle injuries, temporomandibular joint (TMJ) disorder, piriformis syndrome, sciatica, sacroiliac (SI) joint dysfunction, and osteonecrosis; Biological preparations for the treatment of autoimmune and inflammatory conditions including multiple sclerosis (MS), Crohn’s disease, and rheumatoid arthritis; Biological preparations for the treatment of neurological conditions including stroke, dementia, Parkinson’s disease, Huntington’s disease, spinal cord injury, post-concussion syndrome, and autism spectrum disorder; Biological preparations for the treatment of cardiovascular diseases including heart failure, peripheral artery disease, ischemic heart disease, and general cardiovascular disease; Biological preparations for the treatment of metabolic diseases including Type 1 and Type 2 diabetes, and obesity; Biological preparations for the treatment of hematological and immune diseases including, leukemia, lymphoma, myeloma, myelodysplastic syndrome, and myeloproliferative disorders; Biological preparations for the treatment of ophthalmologic conditions including macular degeneration, retinal detachment, and macular hole; Biological preparations for the treatment of liver and gastrointestinal diseases including chronic liver diseases, cirrhosis, liver failure, and Inflammatory bowel disease; Biological preparations for the treatment of chronic pain and degenerative conditions including fibromyalgia, chronic joint pain, and chronic wounds or non-healing ulcers | ACTIVE | Oct 20, 2026 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 27, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 21, 2026 | IUAF | USE AMENDMENT FILED | — |
| Oct 21, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Apr 21, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 24, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 24, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 18, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 2, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 20, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 20, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 20, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 12, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 12, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 12, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 11, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 25, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 25, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 25, 2025 | NWAP | NEW APPLICATION ENTERED | — |